SMMT
Big news, not just biotech jazz
Summit Therapeutics got a boost after partner Akeso released positive topline data from the Phase 3 HARMONi-GI1 trial of ivonescimab in advanced biliary tract cancer. The key punchline: the drug combo beat durvalumab plus chemotherapy on overall survival, which is the kind of endpoint that makes oncology investors sit up straighter.
Why the market is paying attention
This wasn’t just a polite little win on a side metric. The study also met key secondary endpoints, including progression-free survival and objective response rate, which makes the package look a lot less like a one-hit wonder and a lot more like a real contender.
For context, durvalumab plus chemo is currently the preferred first-line immunotherapy regimen in guidelines. So if ivonescimab can outmuscle that standard, that’s a pretty loud statement. Think of it as a rookie challenging the reigning champ and not immediately getting folded.
The fine print you shouldn’t ignore
- Akeso says it will present fuller safety and efficacy data at a future medical congress.
- The trial was run in China, with Akeso handling the data generation and analysis.
- Ivonescimab is approved in China for certain non-small cell lung cancer uses, but it’s still investigational in Summit’s licensed U.S. and Europe territories.
Big picture: this is the kind of readout that can keep the bull case alive, even if the road from “great trial” to “real revenue” still has a few toll booths on it.